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Summary The clinical presentation of Mycobacterium tuberculosis infection varies in patients
with AIDS. We report a case of disseminated tuberculosis in an AIDS patient. The initial
manifestation was masked by fluoroquinolone monotherapy, and subsequently complicated by
acalculous cholecystitis and immune restoration syndrome after antiretroviral therapy.
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Early diagnosis of tuberculosis among AIDS patients is hard to
achieve because of varied clinical presentations. Moreover,
fluoroquinolone as a common agent for bacterial pneumonia
might mask and delay the diagnosis of tuberculosis in ende-
mic areas. The article also talked about immune restorationPublished by Elsevier Ltd. All rights reserved.
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Those points mentioned above were of the very clinical
importance for AIDS care.
Case report
A 36-year-old homosexual male presented with a dry cough
and prolonged fever for three weeks. He was diagnosed with
an HIV-1 infection during initial admission. Laboratory exam-
ination showed a low CD4 T-cell count (77  106/l) and a
plasma HIV viral load of 12 900 copies of RNA/ml. Imaging
studies, including a chest X-ray and computed tomography
scan, did not detect any abnormality. Acid-fast stains of
sputum smears were negative. A tuberculin skin test using
the Mantoux method was non-reactive. Parenteral ofloxacin
followed by oral ciprofloxacin was administrated concomi-
tantly with antiretroviral therapy (ART; zidovudine, lamivu-
dine and efavirenz) and co-trimoxazole as primary
prophylaxis for Pneumocystis jiroveci infection. Blood cul-
tures for common bacteria and fungi were sterile. After the
above treatment, his fever abated and he was discharged
within one week.
Five days later, he was re-admitted for generalized macu-
lopapular skin eruptions and fever. He also complained of dry
cough and frequent choking upon swallowing. Chest films
revealed infiltrates over the right lower lobe (Figure 1A). Co-
trimoxazole was discontinued and ARTwas shifted to a new
regimen (stavudine, didanosine and nelfinavir) for drug
allergy. Ampicillin/sulbactam and moxifloxacin were pre-
scribed for pneumonia. The fever and skin lesions faded
two days later, but the dry cough persisted. Acid-fast stains
of three sputum specimens failed to find any pathogen. After
a seven-day afebrile period, he experienced spiking fever and
rigors again. A second tuberculin skin test remained non-
reactive. A bone marrow study for worsened thrombocyto-
penia did not reveal evidence of malignancy and infection.Figure 1 (A) A chest PA, posteroanterior view revealed infiltrate
patient was admitted. (B) Progression to bilateral pneumonia and
support on the 18th day of admission.Eighteen days after re-admission (after a total of 32 days
ART), the patient complained of epigastralgia and nausea.
Jaundice and elevated aminotransferases were noted.
Abdominal sonography revealed a thickening of the gall
bladder wall and positive Murphy’s sign. Laparoscopic cho-
lecystectomy was performed the next day for acute chole-
cystitis. An edematous gall bladder was noted, but there was
no stone inside the gall bladder or obstruction of the common
bile duct.
He received ventilation support after an operation for
bilateral pulmonary infiltrates with respiratory distress
(Figure 1B). Acid-fast bacilli were detected in sputum sam-
ples. Anti-tuberculosis agents were given with prednisolone
(0.3 mg/kg daily), in conjunction with ART, and the patient
was weaned from the ventilator two days later. Five weeks
after the operation, he was discharged uneventfully. The
overall clinical course and management of this case is sum-
marized in Figure 2. Mycobacterium tuberculosis was subse-
quently isolated from the bone marrow, gall bladder wall,
sputum and blood.
Discussion
A clinical diagnosis of tuberculosis is mainly based on clinical
suspicion, acid-fast stain and mycobacterial culture. Early
diagnosis of tuberculosis in AIDS patients is well known to be
difficult because of the unusual presentation. This case is an
example of an M. tuberculosis (MTB) infection in an AIDS
patients: a non-reactive tuberculin skin test, a positive
sputum culture for MTB but without typical cavitation and
upper lobe infiltrations in chest images, and frequent extra-
pulmonary diseases.1,2 In the era of highly active ART, active
tuberculosis does not increase the mortality and morbidity of
HIV-1-infected patients.3,4 Early diagnosis and anti-tubercu-
losis therapy remain the cornerstones of limiting the spread
of MTB.s over the right middle and lower lobes (arrowhead) when the
respiratory failure with intubation and mechanical ventilation
Figure 2 Summary of the clinical course and management of an AIDS patient with disseminated tuberculosis and IRS. Amp/sul,
ampicillin/sulbactam; Clinda, clindamycin; FEP, cefepime; Moxi, moxifloxacin; MEM, meropenem; CxR, chest X-ray; VL, viral load;
WBC, white blood cell; Plt, platelet; Bil-T, total bilirubin; RLL, right lower lobe; LC, laproscopic cholecystectomy; culture yieldedM.
tuberculosis.
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lous cholecystitis. The patient presented acute cholecystitis
as one of the manifestations of disseminated tuberculosis in
an advanced stage of HIV infection. Most reported cases in
the literature were not related to HIV infections, and often
occurred in those with cholelithiasis and cystic duct obstruc-
tion.5 On the other hand, over 70% of patients with AIDS and
cholecystitis presented acalculous cholecystitis.6,7 Moreover,
a number of organisms, including cytomegalovirus, micro-
sporidia, cryptosporidium and the M. avium complex, have
been implicated in the etiology of opportunistic infections
involving the gall bladder.6,7 Surgical therapy, either open or
laparoscopic cholecystectomy, improved the outcome of
these patients.6,8 According to the experience of this patient
and previous reports, surgical cholecystectomy with anti-
tuberculosis treatment could provide good chance of a cure
for gall bladder tuberculosis in HIV-infected patients.
Fluoroquinolone (FQ) monotherapy for pulmonary tuber-
culosis is of great concern because initial FQ therapy achieves
clinical improvement and thus decreases the alertness of
healthcare givers.9 The patient received FQ monotherapy
and had a temporary clinical improvement. However, the FQ
therapy failed eventually, with a relapse of fever. A previous
study of 548 patients with pulmonary tuberculosis in Taiwan
revealed that initial FQ monotherapy delays diagnosis and is
associated with a poor outcome for HIV- and non-HIV-infected
patients.10 Moreover, anti-tuberculosis treatment is post-
poned by a median interval of 41 days from the initial visit
among infected patients who are treatedwith FQ empirically.
By contrast, therapy for tuberculosis is delayed by only seven
days among those without antibiotics. Therefore, the pru-
dent use of FQ to treat pulmonary infections in HIV-infected
patients should be emphasized in endemic areas.
Another possible explanation for the acute deterioration of
the clinical condition of our patient was that it is a conse-
quence of immune restoration syndrome (IRS). In this case, a
fall in the plasma HIV viral load after ART, with subsequent
development of recurrent fever and rapid worsening of
respiratory symptoms, provided evidence of possible IRS.11
Risk factors associated with MTB-related IRS include startingART for HIV infection within the first two months of anti-
tuberculosis therapy, extrapulmonaryanddisseminated tuber-
culosis, profound immunocompromised status and a higher
viral load before institution of ART.11,12 The recommended
timing of the initiation of ART is two months after beginning
anti-tuberculosis therapy, which balances the risk of develop-
ing IRS and getting new opportunistic infections due to the
immunocompromised status.13,14 With respect to adjuvant
therapy for IRS, some experts consider that patients with
compromised respiratory function might benefit from steroid
therapy.15,16 Likewise, this patient received adjuvant predni-
solone (0.3 mg/kg daily) for IRS, with ARTand antituberculosis
therapy, and recovered thereafter.
In conclusion, M. tuberculosis infection should be kept in
mind for the diagnosis of AIDS patients who present fever of
unknown origin in endemic areas. Empirical FQ treatment
should be avoided, unless tuberculosis can be excluded.
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